5 research outputs found
Evaluation of Different Bowel Preparations for Small Bowel Capsule Endoscopy: A Prospective, Randomized, Controlled Study
Programa de cribado de cáncer colorrectal de la Comunidad Valenciana: resultados de la primera ronda: 2005-2008
Fundamento: Diferentes estudios de cribado de cáncer colorrectal
(CCR) mediante test de sangre oculta en heces (TSOH) han mostrado
reducciones significativas en la mortalidad por este tumor. El objetivo del
trabajo es describir los resultados de la primera ronda del programa de cribado
de CCR en población de riesgo medio de la Comunidad Valenciana y
valorar su factibilidad y aceptabilidad.
Métodos: Estudio piloto de cribado de cáncer colorrectal mediante la
realización de TSOH bienal. Población diana: 106.000 personas de edades
comprendidas entre 50-69 años (un subgrupo de 70-74 años), de 3 Departamentos
de Salud que mediante correo postal fueron invitadas a participar.
Alas que tuvieron TSOH positivo se les remitió al hospital para la realización
de una colonoscopia. Se calcularon: las tasas de participación, de
positividad del test, de aceptación de la colonoscopia, porcentaje colonoscopias
realizadas y porcentaje y tasa de lesiones precursoras y cánceres
invasores, así como el valor predicitivo positivo del TSOH como indicador
de calidad del programa.
Resultados: La participación alcanzada fue de 35.231 personas
(35,70% de las invitadas). El número de test positivos del TSOH fue de
579 (1,64% del total de test analizados). Aceptaron hacerse colonoscopia
548 personas (tasa de aceptación: 94,69%). Se detectaron 61 CCR, 61 adenomas
de alto riesgo y 153 adenomas de bajo riesgo (tasas del 1,77, 1,77 y
4,46% por 1.000 participantes). Los valores predictivos positivos para
cáncer, adenomas de bajo riesgo y adenomas de alto riesgo fueron de
10,95%, 10,95% y 27,46% respectivamente.
Conclusiones: Los indicadores del programa sugieren que un programa
poblacional de cáncer colorrectal es factible en nuestro contesto ya que
los indicadores de proceso obtenidos son similares a los que se dan en otros
programas realizados en España y Europa
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry
Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS0000479
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry
Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS0000479